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Abstract 
Background: To assess the effectiveness of 
Metformin in correcting anthropometric parameters 
in infertile women with polycystic ovary syndrome. 
Methods: One hundred and seventy women in 
Group A and 145 in Group B fulfilling the clinical 
and biochemical criteria for PCOS were enrolled. 
Group allocation was done by randomization. 
Metformin was started at an oral dose of 500mg/day 
and maintained at 1500mg/ day for 3 months in 
Group A and 6 months in Group B. Anthropometric 
parameters such as waist to hip ratio, subscapularis 
skin fold thickness and BMI (Body Mass Index) were 
calculated before the start of treatment and after 
treatment with metformin. 
Results: Patients were subjected by consecutive 
sampling in the randomised controlled trial.In 
Group A and B waist to hip ratio, subscapularis skin 
fold thickness and body mass index (BMI) decreased 
highly significantly (p=0.000) after treatment with 
Metformin for three and six months respectively. 
When comparison of differences of parameters was 
done from baseline to after treatment values 
significant difference was found in Group B 
(p=0.000) in waist to hip ratio and subscapularis skin 
fold thickness. The difference of BMI showed no 
significant change 
Conclusion:Three and six months treatment with 
Metformin results in decrease in parameters such as 
waist to hip ratio, subscapularis skin fold thickness 
and BMI.Six months treatment with Metformin is 
more beneficial as compared to three months 
treatment as it results in more improvement of 
anthropometric parameters which were deranged in 
polycystic infertile patients. 
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Metformin, Polycystic ovaries  
 
Introduction 
     Polycystic ovary syndrome (PCOS) is the most 
common endocrine disorder among women of fertile 
age. More than 30% of women with PCOS are obese 
(body mass index >30 kg/m2), reflecting primarily 
visceral adiposity.1 Obesity is a prominent feature of 
PCOS, occurring in 40-50% of PCOS patients.2 , 3  
Prevalence of PCOS is increased in overweight and 
obese women when compared to their lean 
counterparts. The prevalence rates of PCOS in 
underweight, normal-weight, overweight, and obese 
women are 8.2, 9.8, 9.9, and 9.0%, respectively. 
Prevalence rates reaches 12.4 and 11.5% in women 
with BMI 35-40 kg/m2 and greater than 40 kg/m2.4 
Increased adiposity, particularly visceral adiposity 
that is reflected by an elevated waist circumference 
(>88 cm [35 in.]) or waist-to-hip ratio, has been 
associated with hyperandrogenaemia, insulin 
resistance, glucose intolerance, and dyslipidemia 5. 
PCOS women tend to have an increased waist-hip 
ratio, (WHR) i.e. abdominal (visceral) obesity 6,7Two 
different types of body fat, predominantly visceral and 
the subcutaneous truncal fat respectively are 
measured by waist circumference and the 
subscapularis skin fold thickness.8 Therefore 
subscapularis skin fold thickness has been postulated 
as a measure to identify the women at risk of 
developing non-insulin dependent diabetes mellitus 
NIDDM.9  Anthropometric parameters suggesting 
insulin resistance are obesity waist to hip ratio >0.85  
and subscapularis skin fold thickness >50 mm.10-13 
Metformin treatment results in improvement of 
anthropometric parameters which are deranged in 
polycystic infertile women. 
 
Patients and Methods  
    The study population included women treated for 
infertility seen during a period of one and half year at 
the Pakistan Institute of Medical Sciences Islamabad 
and Noor Specialized Clinic Islamabad. Written and 
knowledgeable permission was gathered from all the 
participants of the study .Patients having  disturbed 
ovulatory function with chronic oligomenorrhea (cycle 
length > 35 d, less than nine cycles per year) or 
amenorrhea (cycle length >12 wk). 2),typical 
appearance of polycystic ovaries by ultrasound 
according to the criteria of the Rotterdam consensus 
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meeting 2003, were included in the study. Patients 
with thyroid problem, tubal defects or on previous 
medications and patients with azoospermic husbands 
were excluded from the study. 
     The patients in Group A were those who gave 
consent (n=170) to take Metformin for three months 
and Group B patients were those who gave consent 
(n=145) to take Metformin for six months. The 
Metformin drug (oral Biguanide) was started in low 
dose to avoid its side effects. Initially the patients were 
advised to take 500 mg tablet daily. They were given 
half tablet in morning and half in the evening for the 
first week and in the next week 500 mg tablet twice 
that is one in the morning and one in the evening. In 
the third week the dose was increased to 500 mg three 
times daily. In Group A 16 patients discontinued the 
treatment in a period of one month. This included two 
patients with tubal defects and in Group B 11 patients 
discontinued the treatment after a period of 15 days. 
This included one patient with tubal defect. In Group 
A total number of patients who continued the 
treatment of Metformin for three months was 154 and 
in Group B 134 patients continued treatment for six 
months. Anthropometric parameters were measured 
before start of Metformin therapy (Pretreatment) and 
after three months in Group A and six months in 
Group B (Post treatment).  
     Waist and hip circumferences were measured to the 
nearest centimeter with a soft tape according to World 
Health Organization criteria. Waist circumference was 
obtained as the minimum value between the iliac crest 
and the lateral costal margin, whereas hip 
circumference was determined as the maximum value 
over the gluteal region. Subscapularis skin fold 
thickness was measured with a Lange-Caliper (Beta 
Technology, Cambridge, MA) to the nearest 0.1 mm.  It 
is measured below inferior angle of the scapula, at 45° 
to the vertical, along the natural cleavage lines of the 
skin. 13Body Mass Index(BMI) was calculated using the 
equation (weight in kg divided by height in m2) with 
normal    ranging between 17–25.9, overweight 
between 26–30, and obese over 30.1 14 Independent 
sample t-test was used to compare differences of waist 
to hip ratio, subscapularis skin fold thickness and BMI 
 from baseline to after treatment. Paired sample t-test 
was used to compare baseline finding with after 
treatment findings in both groups. p value <0.05 was 
considered significant. 
Results 
      Anthropometric parameters such as waist to hip 
ratio, subscapularis skin fold thickness and BMI 
decreased significantly in Group A and B after 
treatment with Metformin for three and six months 
respectively(Table 1&2).  
Table 1.Comparison of parameters before and 
after treatment in Group A patients who took 
metformin for three months(n=154) 
Parameters Mean S.D p- value 
Before Treatment 
Waist-to-hip ratio 
.8788 .10065 
0.000 * 
After Treatment 
Waist-to-hip ratio 
.8319 .09697 
Before Treatment 
Subscapularis skin 
fold Thickness 
52.7994 4.00835 
0.000 * 
After Treatment 
Subscapularis skin 
fold Thickness 
51.6182 3.45727 
  Before Treatment 
BMI 
31.9182 4.83232 
0.000 * 
After Treatment 
BMI 
30.6006 4.38279 
* Mean difference is Significant at 5% level of significance 
Table 2. Comparison of parameters before and 
after treatment in  Group B patients who took 
metformin for six months(n=134) 
Parameters Mean S.D p value 
Before Treatment 
Waist-to-hip ratio 
.8836 .09667 
0.000 * 
After Treatment 
Waist-to-hip ratio 
.7620 .10043 
Before Treatment 
Subscapularis skin 
fold Thickness 
53.1261 3.87492 
0.000 * 
After Treatment 
Subscapularis skin 
fold Thickness 
50.6978 3.88843 
Before Treatment 
BMI 
32.5366 5.05158 
0.000 * 
After Treatment 
BMI 
.8836 .09667 
* Mean difference is Significant at 5% level of significance 
 
     When comparison of differences of parameters was 
done from baseline to after treatment values 
significant difference was found in Group B in waist to 
hip ratio and subscapularis skin fold thickness(Table 
3). The difference of BMI showed no significant 
change. This shows that longer treatment for six 
months is more beneficial as it results in improvement 
of anthropometric parameters. 
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Table 3.Parameters from baseline to after treatment 
values in Group A who were given Metformin for 
three months and Group B who were given 
Metformin for six months. 
Parameters Groups N Mean S.D p-Value 
Difference 
of Waist-
to-hip ratio 
Group A 154 0.0469 0.12157 
0.000 * 
Group B 134 0.1216 0.09502 
Difference 
of 
Subscapula
ris skin 
fold 
thickness 
Group A 154 1.1812 3.41532 
0.001 * 
Group B 134 2.4284 3.12274 
Difference 
of BMI 
Group A 154 1.3176 3.45965 
0.195 ** 
Group B 134 1.7299 1.33487 
* Mean difference is Significant at 5% level of significance;** Mean 
difference is not Significant at 5% level of significance 
 
Discussion 
    PCOS, most common endocrine disorder among 
women of reproductive age, is considered to be not 
only a reproductive endocrinopathy, but also a 
metabolic disorder. Its morbidity may include 
hyperinsulinemia, insulin resistance, early onset of 
type 2 diabetes mellitus, dyslipidemia, macrovascular 
disease,thrombosis, endometrial hyperplasia and 
carcinoma, and obstructive sleep apnea 14-16 
     The gynoid type of fat distribution develops during 
female puberty and persists during the fertile phase of 
adult life.14 Peripheral fat tissue, especially in the 
lower body region is an important source of extra-
ovarian estrogen synthesis, because the aromatization 
from androgens to estrogens takes place there.14 It is 
important to note that the major endocrine symptom 
of PCOS, hyperandrogenicity, is clearly associated 
with a preponderance of fat localized in the upper 
body sites. This sex specific fat distribution, commonly 
called android fat distribution, is associated with 
obesity and a variety of metabolic characteristics, but 
is also mentioned as an indicator of reduced 
reproductive capability of the woman 14. 
    In our study treatment for three months and six 
months resulted in significant decrease in waist to hip 
ratio, subscapularis skin fold thickness and BMI. The 
results show that longer treatment for six months is 
more beneficial as it results in improvement of 
anthropometric parameters. Obesity was reported in 
PCOS patients treated with Metformin for three 
months and six months. 17 Chinese PCOS patients and 
Italian PCOS patients showed low values for BMI.13,18 
Significant decrease in BMI was observed in U.K 
PCOS patients who were treated with metformin for 
14 weeks 18. Similarly the PCOS patients treated with 
metformin for six months showed significant decrease 
in BMI. 19,20 Statistically no significant decrease in BMI 
was seen in PCOS with Metformin treatment. 21, 
22Studies showed varied results for changes in 
anthropometric parameters in patients with PCOS, 
after Metformin treatment. 22-15 
     The results of the present study indicate higher 
baseline value of subscapularis skin fold thickness. 
The high value of adiposity indicated insulin 
resistance as subcutaneous truncal abdominal fat and 
insulin resistance show strong association.24  On other 
hand, visceral adiposity is predicted by waist 
circumference also designates insulin resistance.25 Two 
types of body fat i.e. visceral and subcutaneous truncal 
fat measured by waist circumference and 
subscapularis skin fold thickness are strongly but 
independently correlated with insulin resistance.24-25  
 
Conclusion 
Metformin is effective in correcting the anthropometric 
parameters in polycystic infertile women. The six 
months treatment with Metformin is more beneficial as 
compared to three months treatment. 
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